Paving the road to compliance: Serialisation standardisation through OPEN-SCS (White Paper)
At $200 billion annually, fake pharmaceutical drugs make up the largest, global counterfeit market.
While less than one percent of counterfeit drugs are sold in industrialised nations, such as the United States, 10 to 30 percent of medicines sold in developing countries are counterfeit. In some countries, this number is as high as 70 percent. The federal mandate, Drug Supply Chain Security Act (DSCSA), enacted in November 2015, attempts to combat this problem by outlining a timeline of serialisation mandates that stretch all the way to 2024. It is expected that the majority of the global drug supply will fall under some type of serialisation requirement by 2018.